Publication Name	World Journal of Gastroenterology
Manuscript ID	95157
Country	United States

Received	2024-04-02 22:23
Peer-Review Started	2024-04-02 22:23
To Make the First Decision
Return for Revision	2024-05-01 04:18
Revised	2024-05-10 13:33
Second Decision	2024-05-30 02:41
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-05-30 06:01
Articles in Press	2024-05-30 06:01
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-06-20 05:26
Publish the Manuscript Online	2024-06-25 10:41

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors
Manuscript Source	Invited Manuscript
All Author List	Bansi P Savaliya, Ramin Shekouhi, Fatima Mubarak, Harsheen K Manaise, Paola Berrios Jimenez, Gabrielle Kowkabany, Reed A Popp, Kyle Popp and Emmanuel Gabriel
ORCID	Author(s) ORCID Number Bansi P Savaliya http://orcid.org/0009-0004-4293-807X Ramin Shekouhi http://orcid.org/0000-0002-3784-5280 Fatima Mubarak http://orcid.org/0009-0003-4544-4350 Harsheen K Manaise http://orcid.org/0009-0000-6429-8676 Reed A Popp http://orcid.org/0000-0003-3378-377X Kyle Popp http://orcid.org/0009-0001-5589-0237
Funding Agency and Grant Number
Corresponding Author	Bansi P Savaliya, MD, Doctor, Doctor, Department of Surgery, Medical Academy Named after S.I.Georgievsky of Vernadsky Crimean Federal University, 5/7 Lenina Blvd, Simferopol 295015, Crimea, Russia. bansisavaliya33@gmail.com
Key Words	Hepatitis B virus; Reactivation; Chronic hepatitis B; Tyrosine-kinase inhibitor; Immunomodulators; Immunosuppressant; Nucleoside analogue; Hemato-oncology
Core Tip	Hepatitis B virus reactivation (HBVr) remains a major concern in patients treated with Immunosuppressants and immunomodulators in oncological settings. Patients harboring either overt or occult HBV infection may encounter HBV reactivation during immunosuppressive therapy. The likelihood of HBV reactivation is linked to the patient’s immune status and the initial condition of HBV infection. Depending on the risk, reactivation can be classified as low (< 1%), intermediate (1%-10%), and high (> 10%), It is important to administer nuclei(t)side analogs of high genetic barriers before and during antineoplastic treatment to prevent reactivation. The safety and effectiveness of immunomodulators are investigated. However, during treatment, clinical monitoring of liver enzymes and HBV DNA is required, and a prospective study is needed to determine appropriate antiviral therapy.
Publish Date	2024-06-25 10:41
Citation	<p>Savaliya BP, Shekouhi R, Mubarak F, Manaise HK, Jimenez PB, Kowkabany G, Popp RA, Popp K, Gabriel E. Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors. <i>World J Gastroenterol</i> 2024; 30(24): 3052-3058</p>
URL	https://www.wjgnet.com/1007-9327/full/v30/i24/3052.htm
DOI	https://dx.doi.org/10.3748/wjg.v30.i24.3052

Full Article (PDF)	WJG-30-3052-with-cover.pdf
Manuscript File	95157_Auto_Edited-YJP.docx
Answering Reviewers	95157-answering-reviewers.pdf
Audio Core Tip	95157-audio.m4a
Conflict-of-Interest Disclosure Form	95157-conflict-of-interest-statement.pdf
Copyright License Agreement	95157-copyright-assignment.pdf
Peer-review Report	95157-peer-reviews.pdf
Scientific Misconduct Check	95157-scientific-misconduct-check.png
Scientific Editor Work List	95157-scientific-editor-work-list.pdf
CrossCheck Report	95157-crosscheck-report.pdf